Literature DB >> 11384902

Impact of clozapine on completed suicide.

M J Sernyak1, R Desai, M Stolar, R Rosenheck.   

Abstract

OBJECTIVE: Clozapine has been found to be superior to typical neuroleptics in ameliorating the symptoms of refractory schizophrenia. This study evaluated clozapine's effect on the rate of death due to suicide.
METHOD: All patients over a 4-year period who initiated treatment with clozapine while hospitalized within the Department of Veterans Affairs (VA) system (N=1,415) were matched with a schizophrenic control group (N=2,830) by propensity scoring-a widely accepted statistical method that has been used relatively little in psychiatric research. Centralized VA databases and a national death registry were used to identify all deaths within the two groups, along with listed causes, for the 3 years after discharge.
RESULTS: Veterans exposed to clozapine while inpatients were significantly less likely to die during the follow-up period than those in the control group, but this was entirely attributable to the much lower rate of death due to respiratory disorders in the clozapine group. There were no significant differences in rates of suicide or accidental death.
CONCLUSIONS: These results fail to support the hypothesis that clozapine treatment is associated with significantly fewer deaths due to suicide.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11384902     DOI: 10.1176/appi.ajp.158.6.931

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  15 in total

Review 1.  If suicide is a public health problem, what are we doing to prevent it?

Authors:  Kerry L Knox; Yeates Conwell; Eric D Caine
Journal:  Am J Public Health       Date:  2004-01       Impact factor: 9.308

Review 2.  Suicidality in schizophrenia: a review of the evidence for risk factors and treatment options.

Authors:  Herbert Y Meltzer
Journal:  Curr Psychiatry Rep       Date:  2002-08       Impact factor: 5.285

Review 3.  A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods.

Authors:  Til Stürmer; Manisha Joshi; Robert J Glynn; Jerry Avorn; Kenneth J Rothman; Sebastian Schneeweiss
Journal:  J Clin Epidemiol       Date:  2005-10-13       Impact factor: 6.437

4.  Propensity scores: method for matching on multiple variables in down syndrome research.

Authors:  Jennifer Urbano Blackford
Journal:  Intellect Dev Disabil       Date:  2009-10

Review 5.  Managing suicide risk in patients with schizophrenia.

Authors:  John Kasckow; Kandi Felmet; Sidney Zisook
Journal:  CNS Drugs       Date:  2011-02       Impact factor: 5.749

6.  Time trends and predictors of suicide among mental health outpatients in the Department of Veterans Affairs.

Authors:  Mayur M Desai; Robert A Rosenheck; Rani A Desai
Journal:  J Behav Health Serv Res       Date:  2007-11-08       Impact factor: 1.505

Review 7.  The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements.

Authors:  Robert W Buchanan; Julie Kreyenbuhl; Deanna L Kelly; Jason M Noel; Douglas L Boggs; Bernard A Fischer; Seth Himelhoch; Beverly Fang; Eunice Peterson; Patrick R Aquino; William Keller
Journal:  Schizophr Bull       Date:  2009-12-02       Impact factor: 9.306

8.  Gabapentin adjunctive to risperidone or olanzapine in partially responsive schizophrenia: an open-label pilot study.

Authors:  Adel Gabriel
Journal:  Neuropsychiatr Dis Treat       Date:  2010-10-29       Impact factor: 2.570

9.  Suicidality and second generation antipsychotics in schizophrenia patients: a case-controlled retrospective study during a 5-year period.

Authors:  Y Barak; I Mirecki; H Y Knobler; Z Natan; D Aizenberg
Journal:  Psychopharmacology (Berl)       Date:  2004-02-04       Impact factor: 4.530

Review 10.  Suicidal behaviour in bipolar disorder: risk and prevention.

Authors:  Leonardo Tondo; Göran Isacsson; Ross Baldessarini
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.